Drilldown: Medicines

DMT (1) · Psilocybin (1)

None (1) · COMP360 (Compass Pathways, investigational synthesized clinical formulation) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

5-HT2A partial agonist; sigma-1 agonist (1) · Prodrug to [[Psilocin|psilocin]] (4-hydroxy-N,N-dimethyltryptamine), a partial agonist at the [[Receptor:5-HT2A|5-HT2A]] serotonin receptor; the action that defines the classical-psychedelic mechanism (1)

None (1) · (investigational) '"`UNIQ--vote-000000EF-QINU`"', '"`UNIQ--vote-000000F0-QINU`"', '"`UNIQ--vote-000000F1-QINU`"', '"`UNIQ--vote-000000F2-QINU`"', '"`UNIQ--vote-000000F3-QINU`"' (1)

None (1) · Modern clinical-trial standard: 25 mg synthesized psilocybin, single oral dose with psychological support (1)

None (1) · Synthesized psilocybin capsules (COMP360 and other investigational formulations); dried whole [[Psilocybe|Psilocybe]] mushrooms (variable potency, no legal supply chain in most jurisdictions); psilocybin truffles (Psilocybe sclerotia, legal in the Netherlands) (1)

None (1) · Not FDA-approved; clinical-trial protocols use up to 30 mg in adult investigational dosing (1)

None (1) · Oral (1)

None (1) · 20-45 min subjective onset; psilocin formation from psilocybin requires intestinal and hepatic alkaline phosphatase (1)

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

9–12 minutes (intravenous) (1) · Psilocin: ~2-3 h; psilocybin itself is a prodrug, dephosphorylated within minutes of absorption (1)

None (1) · Oral bioavailability of psilocin from administered psilocybin approximately 50% (1)

None (1) · Not studied in human pregnancy; no approved clinical use in any population (1)

None (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)